Watch this video where our MD and CEO, Jonathan Hunt, shares his perspective on the financial year gone by, and the outlook for FY24. Syngene’s sustained positive performance in the fourth quarter delivered strong full-year results. Revenue from operations in Q4 grew by 31%, while full-year revenue from operations in FY 23 grew by 23%. To read the press release, click here.
- Solutions
- Other Drug Modalities
- SynVent Integrated Drug Discovery
-
SynVent Integrated Drug Discovery
SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
-
- Industries
- Emerging Biopharma
-
Emerging Biopharma
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
-
- Dedicated Centers
-
Dedicated Centers
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
-
- Center for Advanced Protein Studies (CAPS)
-
Center for Advanced Protein Studies (CAPS)
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
-
- Other Drug Modalities
- Investors
-
